Last reviewed · How we verify
Influenza (Influenza and COVID-19 Combination A)
This is a 5-7 sentence executive brief for pharma professionals. The drug is Influenza and COVID-19 Combination A developed by BioNTech SE. It is marketed and has a revenue of $21.2B. The key indications include aches, cold symptoms, cramping, discomfort, and fatigue. The drug has undergone 24 trials and has 0 publications. It is a combination vaccine for influenza and COVID-19.
At a glance
| Generic name | Influenza and COVID-19 Combination A |
|---|---|
| Sponsor | BioNTech |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Target | SARS-CoV-2 spike protein and influenza hemagglutinin protein |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Symptoms of colds and flu
Common side effects
- Injection site pain (PAIN)
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Chills (CHILLS)
- Myalgia (MUSCLE PAIN)
- Arthralgia (JOINT PAIN)
- Diarrhoea (DIARRHEA)
- Injection site erythema (REDNESS)
- Pyrexia (FEVER)
- Injection site swelling (SWELLING)
- Vomiting (VOMITING)
- Upper respiratory tract infection
Drug interactions
- Amiodarone
- Azithromycin
- Cobicistat
- Dofetilide
- Erythromycin
- Fosamprenavir
- Indinavir
- Lopinavir
- Nelfinavir
- Ritonavir
- Saquinavir
- Tipranavir
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
- A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults (PHASE2)
- Covid-19 and Influenza Oral Vaccine Study (PHASE1)
- A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza CI brief — competitive landscape report
- Influenza updates RSS · CI watch RSS
- BioNTech portfolio CI